Remsima
Drug timelines are a Plus or Pro feature.
7 regulatory and trial events tracked for Remsima, covering 2022-02-21 to 2026-04-23. Get the full timeline:
Most recent: EMA Authorised: Remsima (infliximab) — Celltrion Healthcare Hungary Kft.